BioWorld Asia

Feb. 4, 2004

Cyclacel's Fourth Round Gets $39M For Cell Cycle Inhibitors

LONDON - Cyclacel Ltd. raised £21.3 million (US$39 million) in an oversubscribed fourth round of private funding, bringing its total private equity raised to date to $123 million. (BioWorld International) Read More

Acambis Moving R&D Core To U.S.,Cutting Work Force By 40

Predatory Bacterium Could Hold Key To Antibiotic Treasure Trove

With GLP-2 In Osteoporosis Focus, Sanos Raises $10M

PharmaMar Cutting Staff To Conserve Cash For Yondelis

ExonHit Raises Additional EUR8.3M; Now Has Cash To Last Into 2006

Another European Request For Lifting GMO Moratorium

Dissent With Partner Spurs Cutbacks At Micromet AG

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...